Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127076061 | 12707606 | 1 | I | 20160816 | 20160823 | 20160901 | 20160901 | EXP | PHHO2016US012352 | SANDOZ | 66.93 | YR | M | Y | 97.78000 | KG | 20160901 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127076061 | 12707606 | 1 | PS | FUROSEMIDE TABLETS USP | FUROSEMIDE | 1 | Oral | 40 MG, BID | 40640 | MG | 18569 | 40 | MG | TABLET | BID | ||||
| 127076061 | 12707606 | 2 | SS | FUROSEMIDE TABLETS USP | FUROSEMIDE | 1 | 40640 | MG | 18569 | TABLET | |||||||||
| 127076061 | 12707606 | 3 | SS | METOLAZONE. | METOLAZONE | 1 | Oral | 5 MG, TID | 6105 | MG | 0 | 5 | MG | TABLET | TID | ||||
| 127076061 | 12707606 | 4 | SS | DIOVAN | VALSARTAN | 1 | Oral | CODE NOT BROKEN | 0 | TABLET | |||||||||
| 127076061 | 12707606 | 5 | SS | BLINDED LCZ696 | SACUBITRIL | 1 | Oral | CODE NOT BROKEN | 0 | TABLET | |||||||||
| 127076061 | 12707606 | 6 | SS | BLINDED NO TREATMENT RECEIVED | INVESTIGATIONAL PRODUCT | 1 | Oral | CODE NOT BROKEN | 0 | TABLET | |||||||||
| 127076061 | 12707606 | 7 | SS | DIOVAN | VALSARTAN | 1 | Oral | CODE NOT BROKEN | 0 | TABLET | |||||||||
| 127076061 | 12707606 | 8 | SS | BLINDED LCZ696 | SACUBITRIL | 1 | Oral | CODE NOT BROKEN | 0 | TABLET | |||||||||
| 127076061 | 12707606 | 9 | SS | BLINDED NO TREATMENT RECEIVED | INVESTIGATIONAL PRODUCT | 1 | Oral | CODE NOT BROKEN | 0 | TABLET | |||||||||
| 127076061 | 12707606 | 10 | C | INSULIN GLARGINE | INSULIN GLARGINE | 1 | Subcutaneous | 46 U, QD | 0 | 46 | DF | QD | |||||||
| 127076061 | 12707606 | 11 | C | POTASSIUM | POTASSIUM | 1 | Oral | 30 MEQ, TID | 0 | 30 | MEQ | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127076061 | 12707606 | 1 | Fluid retention |
| 127076061 | 12707606 | 2 | Cardiac failure chronic |
| 127076061 | 12707606 | 3 | Fluid retention |
| 127076061 | 12707606 | 4 | Cardiac failure |
| 127076061 | 12707606 | 5 | Cardiac failure |
| 127076061 | 12707606 | 6 | Cardiac failure |
| 127076061 | 12707606 | 10 | Type 2 diabetes mellitus |
| 127076061 | 12707606 | 11 | Hypokalaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127076061 | 12707606 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127076061 | 12707606 | Diabetes mellitus | |
| 127076061 | 12707606 | Hyperosmolar hyperglycaemic state | |
| 127076061 | 12707606 | Hypokalaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127076061 | 12707606 | 1 | 20150328 | 20160816 | 0 | |
| 127076061 | 12707606 | 3 | 20150707 | 20160816 | 0 | |
| 127076061 | 12707606 | 4 | 20160811 | 20160816 | 0 | |
| 127076061 | 12707606 | 5 | 20160811 | 20160816 | 0 | |
| 127076061 | 12707606 | 6 | 20160811 | 20160816 | 0 | |
| 127076061 | 12707606 | 7 | 20160824 | 0 | ||
| 127076061 | 12707606 | 8 | 20160824 | 0 | ||
| 127076061 | 12707606 | 9 | 20160824 | 0 | ||
| 127076061 | 12707606 | 10 | 20160203 | 20160816 | 0 | |
| 127076061 | 12707606 | 11 | 20160405 | 20160816 | 0 |